Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06140-w ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, 2024. Verfasst von Giorgia Ranucci und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Janus Kinase 2, Hematopoietic Stem Cell Transplantation, Germ-Line Mutation. Die Arbeit nennt 10 Literaturangaben. Gefördert von: Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Recently, germline variants have also been found as contributors of disease etiology in myeloproliferative neoplasms (MPN). The consideration of such inherited traits is crucial for clinical management of patients, particularly with regards to indication for allogeneic hematopoietic cell transplant (allo-HCT) and donor selections. Herein, we describe the very instructive case of a 49-year-old woman diagnosed with JAK2 V617F-positive primary myelofibrosis (PMF) who was found to also carry a germline variant in the SH2B3 gene, detailing clinical management, donor selection process for allo-HCT purposes, and appropriate genetic counseling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
- Medical Genetics Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, Rome, Italy.
- Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy.
- Department of Hematology, Polo Universitario Pontino, S.M. Goretti Hospital, Latina, Italy.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. enrico.attardi@gmail.com.
- Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy. enrico.attardi@gmail.com.
Förderung
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Ranucci, G., Page, C., Marchionni, E., Minotti, C., Silvestrini, G., Gastaldi, S., Pacitto, G., Cicconi, L., Biagi, A., Ferradini, V., Attardi, E., Novelli, G., Sangiuolo, F., Voso, M. T., & Gurnari, C. (2024). Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant. Annals of Hematology. https://doi.org/10.1007/s00277-024-06140-w
Vancouver
Ranucci G, Page C, Marchionni E, Minotti C, Silvestrini G, Gastaldi S, et al. Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant. Annals of Hematology. 2024. doi:10.1007/s00277-024-06140-w
BibTeX
@article{Ranucci2024,
author = {Ranucci, Giorgia and Page, Camilla and Marchionni, Enrica and Minotti, Chiara and Silvestrini, Giorgia and Gastaldi, Susanna and Pacitto, Giada and Cicconi, Laura and Biagi, Annalisa and Ferradini, Valentina and Attardi, Enrico and Novelli, Giuseppe and Sangiuolo, Federica and Voso, Maria Teresa and Gurnari, Carmelo},
title = {Donor selection for allogeneic hematopoietic cell transplant in a patient with JAK2 V617F primary myelofibrosis and SH2B3/LNK germline variant},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06140-w}
}
EUVIMED